Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 13, Issue 9, 2014, Pages 2184-2193

  Zhang, Yi Xiang ^a,b   Sicinska, Ewa ^a,b   Czaplinski, Jeffrey T ^a,b   Remillard, Stephen P ^a,b   Moss, Samuel ^a,b   Wang, Yuchuan ^c   Brain, Christopher ^d   Loo, Alice ^d   Snyder, Eric L ^e,f,h   Demetri, George D ^a,b   Kim, Sunkyu ^d   Kung, Andrew L ^g   Wagner, Andrew J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g NewYork Presbyterian Hospital   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA;

ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; CANCER TRANSPLANTATION; CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; GENE DOSAGE; HUMAN; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MALE; METABOLISM; MOUSE; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PHOSPHORYLATION; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; RNA, SMALL INTERFERING;

EID: 84907200254     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0387     Document Type: Article

References (37)

1. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002; 2:910-7.
2. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 8:714-24.
3. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phos-phorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98: 859-69.
4. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1:222-31.
5. Zarkowska T, Mittnacht S. Differential phosphorylation of the retino-blastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 1997; 272:12738-46.
6. Bockstaele L, Kooken H, Libert F., Paternot S, Dumont JE, de Launoit Y, et al. Regulated activating Thr172 phosphorylation of cyclin-depen-dent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors". Mol Cell Biol 2006; 26:5070-85.
7. Bockstaele L, Coulonval K, Kooken H., Paternot S, Roger PP. Regulation of CDK4. Cell Div 2006; 1:25.
8. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009; 220:292-6.
9. Musgrove EA, Caldon CE, Barraclough J, Stone A., Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11: 558-72.
10. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Onco-gene 1999; 18:5311-7.
11. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602:73-87.
12. Sirvent N, Coindre JM, Maire G, Hostein I., Keslair F, Guillou L, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybrid-ization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 2007; 31:1476-89.
13. Binh MB, Sastre-Garau X, Guillou L., de Pinieux G, Terrier P, Lagace R., et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005; 29:1340-7.
14. Henze J, Bauer S. Liposarcomas. Hematol Oncol Clin North Am 2013; 27:939-55.
15. Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma 2011; 2011:483154.
16. Crago AM, Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 2011; 23:373-8.
17. Ghadimi MP, Al-Zaid T, Madewell J., Peng T, Colombo C, Hoffman A., et al. Diagnosis, management, and outcome of patients with dediffer-entiated liposarcoma systemic metastasis. Ann Surg Oncol 2011; 18: 3762-70.
18. Helias-Rodzewicz Z, Pedeutour F, Coindre J.M., Terrier P., Aurias A. Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma. Genes Chromosomes Cancer 2009; 48:943-52.
19. Barretina J, Taylor BS, Banerji S, Ramos A.H., Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010; 42:715-21
20. Miller ML, Molinelli EJ, Nair JS, Sheikh T, Samy R, Jing X, et al. Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. Sci Signal 2013; 6: ra85.
21. Dickson MA, Tap WD, Keohan M.L., D'Angelo SP, Gounder MM, Antonescu C.R., et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or ded-ifferentiated liposarcoma. J Clin Oncol 2013; 31:2024-8.
22. Pedeutour F, Forus A, Coindre J.M., Berner JM, Nicolo G, Michiels JF, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999; 24: 30-41.
23. Snyder EL, Sandstrom DJ, Law K, Fiore C., Sicinska E, Brito J, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol 2009; 218:292-300.
24. Peng XD, Xu PZ, Chen M.L., Hahn-Windgassen A, Skeen J, Jacobs J., et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003; 17:1352-65.
25. Kim S, Loo A, Chopra R., Caponigro G, Huang A, Vora S., et al. LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6-reactivating Rb in cancer. Mol Cancer Ther 2013; 12:11s. (suppl; abstr PR02).
26. Chen Z, Cheng K, Walton Z., Wang Y, Ebi H, Shimamura T., et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483:613-7.
27. Infante JR, Shapiro GI, Witteveen P.O., gerecitano JF, Ribrag V, chugh R, et al. Phase I multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas. Mol Cancer Ther 2013; 12:11s. (suppl; abstr A276).
28. Fry DW, Harvey PJ, Keller P.R., Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427-38
29. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 2012; 22:438-51.
30. Sleijfer S, Wagner AJ. The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases. J Clin Oncol 2012; 30:896-8.
31. Schwartz GK, LoRusso PM, Dickson M.A., Randolph SS, Shaik MN, Wilner KD, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1). Br J Cancer 2011; 104:1862-8.
32. Wang TC, Cardiff RD, Zukerberg L, Lees E., Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369:669-71.
33. Momand J, Zambetti GP, Olson D.C., George D., Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-45.
34. Haupt Y, Maya R, Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.
35. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
36. Muller CR, Paulsen EB, Noordhuis P, Pedeutour F., Saeter G, Mykle-bost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 2007; 121:199-205.
37. Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J., et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposar-coma: an exploratory proof-of-mechanism study. Lancet Oncol 2012; 13:1133-40.